NCT02453009View on ClinicalTrials.gov

Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2019

Conditions
Prostatic Neoplasms
Interventions
DRUG

Docetaxel

Pharmaceutical form:solution Route of administration: intravenous

DRUG

Prednisone

Pharmaceutical form:tablet Route of administration: oral

DRUG

Enzalutamide

Pharmaceutical form : soft gelatin capsules Route of administration: oral

Trial Locations (1)

38122

Santa Chiara Hospital, Trento

All Listed Sponsors
lead

Santa Chiara Hospital

OTHER

NCT02453009 - Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter